How iNKT immune cells after allogeneic stem cell transplant relate to transplant complications
Official title: Standardised Quantification of Invariant NKT Cells Using DryTube Technology and Flow Cytometry in Patients Who Have Undergone Allogeneic Haematopoietic Stem Cell Transplantation.
Run by University Hospital Pilsen · NCT07570407 · Data updated 2026-11-12
This study tests whether levels of invariant NKT cells in the blood after an allogeneic stem cell transplant can be linked to complications like GvHD, infections, or relapse in patients with AML.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | University Hospital Pilsen Academic / other |
| Locations | 1 site (Pilsen, Czechia) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | January 31, 2029 |
| Registry record updated | August 13, 2026 |
| Trial ID | NCT07570407 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with AML undergoing first allogeneic HSCT from peripheral blood stem cells, in complete remission, with good performance status.
✕Probably not a fit
Patients with non-AML diseases, active malignancy, prior transplant, or poor performance status may not benefit from this biomarker approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, multicenter study tracks iNKT cells in patients undergoing allogeneic HSCT for AML. Researchers will standardize blood-based monitoring of iNKT cells using flow cytometry and explore associations between iNKT cell counts and post-transplant events such as GvHD, CMV infection, relapse, and overall immune reconstitution. The aim is to determine whether iNKT cell levels could serve as a biomarker to identify patients at higher risk for complications. Enrollment is limited to patients in complete remission at HSCT with PBSC as the graft source and no prior transplant. The study is led by University Hospital Pilsen in the Czech Republic and involves blood draws as the primary intervention.
Why it matters
Potential benefit: If successful, monitoring iNKT cells could help identify patients at higher risk of complications and guide personalized post-transplant care.
How similar studies have gone: Previous data suggest iNKT cell levels relate to GvHD and relapse, but standardised multicenter biomarker studies are limited and this approach is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis: AML (exlusion of secondary disease) * Disease status at time of HSCT: complete remission * Karnofsky performance status: ≥80% * Source of HSC: PBSC Exclusion Criteria: * Prior transplant * Uncontrolled Malignancy
Where it's running
-
University Hospital Pilsen
Pilsen, Czechia, Czechia Recruiting
Study contacts
- Study coordinator: Monika Holubová, MSc.
- Email: holubovam@fnplzen.cz
- Phone: +420 377 103 991
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment of relapsed or refractory acute myeloid leukemia with a new drug combination
This study is testing a new combination of drugs to see if it can help people with relapsed or refractory acute myeloid leukemia feel better and improve their treatment outcomes.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Characterization of CD180 Protein Expression in Myeloid Blood C cancers
This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.
-
Personalized AML: Find biomarkers to predict response to venetoclax
This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
MAX-40279 with Venetoclax and Azacitidine for unfit newly diagnosed AML
This study tests MAX-40279 added to venetoclax and azacitidine in older or unfit adults newly diagnosed with AML to see if it is safe and shows activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.